Opko Health Inc. (OPK) Stock Price

OPKStock

$1.53+2.00%52W

Market Cap$1.14B

P/E—

PEG Ratio93.65

Div yield—

Beta1.53

OPK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)20.86%

Price vs S&P 500 (4W)-8.14%

PEG Ratio93.65

VGM Score63.71

Book Value / Share (Quarterly)$1.59

P/TBV (Annual)1.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)3.64%

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)9.50%

Gross Margin (TTM)38.00%

Net Profit Margin (TTM)-23.93%

EPS (TTM)$-0.10

10-Day Avg Trading Volume8.16M

EPS Excl Extra (TTM)$-0.10

Revenue Growth (5Y)0.78%

EPS (Annual)$-0.30

ROI (Annual)-13.96%

Gross Margin (Annual)36.84%

Net Profit Margin (5Y Avg)-12.72%

Cash / Share (Quarterly)$0.40

Revenue Growth QoQ (YoY)-0.64%

ROA (Last FY)-11.68%

Revenue Growth TTM (YoY)-28.95%

EBITD / Share (TTM)$-0.08

ROE (5Y Avg)-9.40%

Operating Margin (TTM)-16.52%

Cash Flow / Share (Annual)$-0.25

P/B Ratio0.96x

P/B Ratio (Quarterly)0.96x

Net Income / Employee (Annual)$-99,200

EV / Revenue (TTM)2.30x

Net Interest Coverage (TTM)-5.85x

ROA (TTM)-3.83%

EPS Growth QoQ (YoY)-22.63%

EV / EBITDA (TTM)7.82x

EPS Incl Extra (Annual)$-0.30

Current Ratio (Annual)3.97x

Quick Ratio (Quarterly)2.85x

3-Month Avg Trading Volume3.85M

52-Week Price Return2.00%

Revenue / Employee (TTM)$206,608,700,000

Tangible BV / Share (Quarterly)$0.69

P/S Ratio (Annual)1.32x

Asset Turnover (Annual)0.43x

52-Week High$1.77

Operating Margin (5Y Avg)-9.74%

EPS Excl Extra (Annual)$-0.30

CapEx CAGR (5Y)-11.98%

Tangible BV CAGR (5Y)-1.70%

26-Week Price Return30.77%

Quick Ratio (Annual)3.43x

13-Week Price Return28.57%

Total Debt / Equity (Annual)0.28x

Current Ratio (Quarterly)3.35x

Enterprise Value$1.19B

Revenue / Share Growth (5Y)-4.17%

Asset Turnover (TTM)0.40x

Book Value / Share Growth (5Y)-9.31%

Revenue / Employee (Annual)$379,600

Inventory Turnover (Annual)8.92x

Pretax Margin (Annual)-21.35%

Cash / Share (Annual)$0.48

3-Month Return Std Dev93.35%

Gross Margin (5Y Avg)34.81%

Net Income / Employee (TTM)$-32,000

EBITDA Interim CAGR (5Y)11.35%

ROE (Last FY)-17.80%

Net Interest Coverage (Annual)-25.97x

EPS Basic Excl Extra (Annual)$-0.30

P/FCF (TTM)33.18x

Receivables Turnover (TTM)7.21x

Total Debt / Equity (Quarterly)0.30x

EPS Incl Extra (TTM)$-0.10

Receivables Turnover (Annual)5.19x

ROI (TTM)-4.58%

P/S Ratio (TTM)1.35x

Pretax Margin (5Y Avg)-13.74%

Revenue / Share (Annual)$1.15

Tangible BV / Share (Annual)$0.73

Free OCF CAGR (5Y)10.98%

Price vs S&P 500 (52W)-13.53%

EPS Growth TTM (YoY)39.22%

Year-to-Date Return21.43%

5-Day Price Return10.87%

EPS Normalized (Annual)$-0.30

ROA (5Y Avg)-6.47%

Net Profit Margin (Annual)-21.87%

Month-to-Date Return-4.97%

Cash Flow / Share (TTM)$-0.14

EBITD / Share (Annual)$-0.17

Operating Margin (Annual)-18.18%

LT Debt / Equity (Annual)0.26x

ROI (5Y Avg)-7.40%

LT Debt / Equity (Quarterly)0.29x

EPS Basic Excl Extra (TTM)$-0.10

P/TBV (Quarterly)2.21x

P/B Ratio (Annual)0.76x

Inventory Turnover (TTM)5.45x

Pretax Margin (TTM)-24.69%

Book Value / Share (Annual)$1.67

Price vs S&P 500 (13W)25.89%

Beta1.53x

P/FCF (Annual)157.21x

Revenue / Share (TTM)$1.15

ROE (TTM)-5.88%

52-Week Low$0.98

vGradeB

gGradeC

mGradeA

vgmGradeB

OPK Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 27, 2026	-$0.11	-$0.03	+76.27%(+$0.08)
Q1 2026	Apr 28, 2026	-$0.07	-$0.07	-6.22%(-$0.00)
Q4 2025	Feb 26, 2026	-$0.07	-$0.04	+48.86%(+$0.03)
Q3 2025	Oct 29, 2025	-$0.04	$0.03	+166.67%(+$0.08)
Q2 2025	Jul 31, 2025	-$0.10	-$0.08	+17.90%(+$0.02)

OPK Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.82

3.90

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
OPKOpko Health Inc.	B	C	A	1.3x	-29.0%	38.0%	—	$1.53
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Opko Health Inc.

OPKO Health is a diversified biotechnology company with pharmaceutical and diagnostics segments operating globally. Its diagnostics division, which generates the majority of revenue, operates clinical and genomics laboratories through BioReference and point-of-care services. The pharmaceutical segment focuses on research, development, and commercial operations across multiple countries.

OPK Next Earnings Report

Report dateOct 28, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.06

Revenue estimate$136.62M

Also reporting on Oct 28, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

Companies in Related Industries

INBXInhibrx Biosciences, Inc. Common StockBiological Products
EPCEdgewell Personal Care CompanyCosmetics & Toiletries
CRONCronos Group Inc. Common SharePharmaceutical Preparations
TSHATaysha Gene Therapies, Inc. Common StockBiological Products
ECVTEcovyst Inc.Chemicals
ODDODDITY Tech Ltd. Class A Ordinary SharesCosmetics & Toiletries
IMTXImmatics N.V. Ordinary SharesBiological Products
REPLReplimune Group, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$0.98

High$1.77